Document Detail


Impact of Local and Systemic Alendronate on Simvastatin-Induced New Bone Around Periodontal Defects.
MedLine Citation:
PMID:  22420870     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
Background: Simvastatin has been shown to stimulate new bone growth on rat mandibles, but much of the bone is lost over time. The purpose of this study was to evaluate the impact of a locally- or systemically-applied anti-resorptive agent (alendronate) on simvastatin-induced bone formation in and adjacent to a rat periodontal defect. Methods: Fenestration defects were created over mandibular molar roots in 65 mature female Sprague-Dawley rats. Two weeks later, animals were divided into 8 groups of 8-9 rats and three weekly injections around the defect were applied containing 0.5 mg simvastatin in ethanol (SIM-EtOH), 0.5 mg simvastatin in cyclodextrin-alendronate conjugate (SIM-ALN-CD), EtOH or ALN-CD alone, or no injections. Twenty-four animals were evaluated for new bone width around the defect 21 days after the last injections (short-term), while 41 rats were followed for 48 days (long-term). Two groups of long-term rats also were subjected to 2 weeks of daily systemic alendronate either during or 3-4 weeks after SIM-EtOH injections. Decalcified, hematoxylin & eosin-stained cross-sections of the defect area were analyzed for new bone width, and groups were compared using mixed model analysis of variance. Results: All groups showed nearly 100% bone fill, with no differences among groups in the short-term observations. However, in the long-term animals, 2-3 fold more new bone width (≤ 0.004) was seen around the periphery of the defect with the use of systemic alendronate following SIM-EtOH injections (0.93 ± 0.12 and 0.78 ± 0.11 mm with early and late systemic ALN, respectively), compared to local simvastatin/alendronate preparations (0.32 ± 0.10 mm) or short-term SIM-EtOH injections (0.35 ± 0.10 mm). No significant new cementum formation or ankylosis was noted. Conclusion: The use of a short course of systemic alendronate during the healing period following bone anabolic simvastatin injections has the potential to enhance local bone augmentation.
Authors:
Amy C Killeen; Pota A Rakes; Marian J Schmid; Yijia Zhang; Nagamani Narayana; David B Marx; Jeffrey B Payne; Dong Wang; Richard A Reinhardt
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-3-16
Journal Detail:
Title:  Journal of periodontology     Volume:  -     ISSN:  1943-3670     ISO Abbreviation:  -     Publication Date:  2012 Mar 
Date Detail:
Created Date:  2012-3-16     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8000345     Medline TA:  J Periodontol     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Affiliation:
Department of Surgical Specialties, College of Dentistry, University of Nebraska Medical Center, Lincoln, NE. First two authors contributed equally to this work.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Patient-reported outcomes in trials of incretin-based therapies in patients with type 2 diabetes mel...
Next Document:  Efficacy of Subgingivally Delivered Simvastatin in the Treatment of Type 2 Diabetes Subjects With Ch...